Camilo Garcia

Patrick Flamen7
Alain Hendlisz6
Thomas Guiot3
Antoine Wagner2
7Patrick Flamen
6Alain Hendlisz
3Thomas Guiot
Learn More
UNLABELLED In PET-based patient monitoring, metabolic tumor changes occurring between PET scans are most often assessed visually or by measuring only a few parameters (tumor volume or uptake), neglecting most of the image content. We propose and evaluate a parametric imaging (PI) method to assess tumor changes at the voxel level. METHODS Seventy-eight(More)
Radium-223 dichloride (radium-223) mimics calcium and emits high-energy, short-range alpha-particles resulting in an antitumor effect on bone metastases. This open-label, phase IIa nonrandomized study investigated safety and short-term efficacy of radium-223 in breast cancer patients with bone-dominant disease. Twenty-three advanced breast cancer patients(More)
PURPOSE Medical oncology needs early identification of patients that are not responding to systemic therapy. (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) performed before and early during treatment has been proposed for this purpose. However, the best way to assess the change in FDG uptake between two scans has not been identified. We(More)
INTRODUCTION The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient's unlikelihood of(More)
  • Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte, Nicolas Charette, Marianne Paesmans, Thomas Guiot +2 others
  • 2015
INTRODUCTION Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients' outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-based metabolic response assessment (MRA) might adequately(More)
  • Alain Hendlisz, Amelie Deleporte, Thierry Delaunoit, Raphaël Maréchal, Marc Peeters, Stéphane Holbrechts +17 others
  • 2015
BACKGROUND Tumoral heterogeneity is a major determinant of resistance in solid tumors. FDG-PET/CT can identify early during chemotherapy non-responsive lesions within the whole body tumor load. This prospective multicentric proof-of-concept study explores intra-individual metabolic response (mR) heterogeneity as a treatment efficacy biomarker in(More)
In this paper we report two interesting cases of metastatic ovarian cancer. The first case is a patient who developed rectal and breast metastases mimicking an inflammatory breast cancer. In the second case, subclinical breast and axillary lymph node metastases were revealed by PET/CT. Metastases in the breast originating from solid tumors are extremely(More)
1 Description Every creative project needs to have an ideation process. A good ideation process relies on a simple yet effective way of putting ideas on the table and sorting through them, also discarding them easily if necessary. However, for this ideation to be successful it has to be a process in which cheap and simple ways of exploring ideas are used(More)
  • 1